A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)

Trial Profile

A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Influenza virus vaccine
  • Indications Herpes zoster; Varicella zoster virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 Aug 2017 Primary endpoint (Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody-non-inferiority) has been met, according to results published in the Vaccine Journal.
    • 19 Aug 2017 Primary endpoint (Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody-non-inferiority) has been met, according to results published in the Vaccine Journal.
    • 19 Aug 2017 Primary endpoint (Geometric Mean Titers of H3N2-specific Influenza Virus Antibody-non-inferiority) has been met, according to results published in the Vaccine Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top